KLK3 and prostate carcinoma: While prostate-specific antigen (PSA) blood-based screening has contributed to favorable stage migration and ostensible improvement in disease-specific survival [2], PSA remains a non-specific marker with limitations in discrimination for clinically significant prostate cancer (csPCa).